Back to Agendas
Collaborate to Innovate: Exploring a Seconds Market
Session Chair(s)
Nermeen Y. Varawalla
Executive Vice President, Global Clinical Trials
Lambda Therapeutic Research, United Kingdom
In light of declining R&D productivity, increasing R&D costs and the impending patent expiration of blockbuster drugs, the pipeline attrition of molecules, especially in the advanced stages of development, where costs of conducting clinical trials are the greatest, have resulted in an alarming rise in R&D costs. With proven safety and efficacy in the initial phases, these molecules possess a potential of being developed into a blockbuster. Developing strategic alliances to outsource or sell such developmental molecules may result in the same being tried for new indications. With existing data, innovative start-ups or smaller pharmaceutical firms can develop new molecules that may cater to huge unmet patient needs across the globe in critical therapeutic areas. This session will examine these strategic partnerships as well as the advantages and challenges of developing a "seconds" market.
Learning Objective : Discuss alternative strategies to boost drug development productivity and promote innovative sourcing to curb research and development cost; Explain the repositioning of drug molecules to address declining rate of pharmaceutical innovation; Discuss the support and development of start-ups and small scale research organizations for strategic development alternatives.
Speaker(s)
Reducing Clinical Development Budgets by Smart Trial Design
Nermeen Y. Varawalla
Lambda Therapeutic Research, United Kingdom
Executive Vice President, Global Clinical Trials
Innovation in Secondary Markets: Modalities
Kiran Marthak, MD, FFPM, FRCP
Lambda Therapeutic Research Ltd., India
Director, Phase 1 & Regulatory
Have an account?